Cox Jacob T, Eliott Dean, Sobrin Lucia
Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA.
J Clin Med. 2021 Mar 2;10(5):981. doi: 10.3390/jcm10050981.
Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a commonly used therapy for numerous retinal diseases. The most commonly used of these medications are bevacizumab, ranibizumab, aflibercept, and brolucizumab. However, intravitreal administration of these agents is also associated with several inflammatory and non-inflammatory adverse events. The three inflammatory adverse events are sterile intraocular inflammation, brolucizumab-associated retinal vasculitis, and post-injection endophthalmitis. This narrative review summarizes the current literature regarding these conditions, including their epidemiology, presentation, management, outcomes, and pathogenesis. The inflammatory adverse events also share a number of overlapping features, which can make them difficult to discern from one another in a clinical context. This review discusses certain distinguishing features of these conditions that may aid providers in discerning between them and establishing the correct diagnosis.
玻璃体内注射抗血管内皮生长因子（anti-VEGF）药物是治疗多种视网膜疾病的常用疗法。这些药物中最常用的是贝伐单抗、雷珠单抗、阿柏西普和布罗卢izumab。然而，玻璃体内注射这些药物也会引发一些炎症性和非炎症性不良事件。三种炎症性不良事件分别是无菌性眼内炎症、布罗卢izumab相关的视网膜血管炎和注射后眼内炎。这篇叙述性综述总结了关于这些病症的当前文献，包括它们的流行病学、临床表现、治疗、预后和发病机制。这些炎症性不良事件也有许多重叠特征，这使得它们在临床环境中难以相互区分。本综述讨论了这些病症的某些显著特征，这些特征可能有助于医生区分它们并做出正确诊断。
